CFI-402411 + pembrolizumab

CFI-402411 + pembrolizumab is an investigational combination therapy for advanced solid malignancies. **CFI-402411** is a first-in-class *small molecule inhibitor* targeting hematopoietic progenitor kinase 1 (HPK1, also called MAP4K1), a pleiotropic negative regulator of immune cell activation. Inhibition of HPK1 by CFI-402411 activates T cells, B cells, and dendritic cells, enhancing anti-tumor immune responses[6][3]. **Pembrolizumab** is a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), approved as immunotherapy for a wide range of cancers. The combination seeks to stimulate immune cell activity (via HPK1 inhibition) and relieve checkpoint inhibition (via PD-1 blockade), with the goal of increased anti-tumor efficacy over either agent alone. Early clinical data indicate promising antitumor responses, especially in head and neck squamous cell carcinoma, and a manageable safety profile[3][5]. The therapy is under investigation in Phase 1/2 trials for adults with previously treated, refractory advanced solid tumors[1][3][5].

Other names

CFI-402411 + pembrolizumab